Dr. Yubin Kang, MD

Dr. Kang practices at Duke University Hospital in Durham, North Carolina, part of Duke University.

Dr. Kang's NPI, 1205046927, was assigned on May 23, 2007. Dr. Kang graduated from The Second Military Medicine Univ in 1985. Dr. Kang's North Carolina license number on file is 2014-01289.

Dr. Kang's primary practice is Duke University Hospital, at 2301 Erwin Rd, Durham, NC 27705 in Durham County. The practice phone is (919) 684-8111.

Dr. Kang's primary practice is Duke University Hospital in Durham, North Carolina, part of Duke University. Dr. Kang is also affiliated with Duke Regional Hospital. The medical group on file is Duke Health Integrated Practice. Dmand AI also links Dr. Kang to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kang practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kang's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kang is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Kang's licenses on file in 3 states: North Carolina, South Carolina and Iowa.

Dmand AI lists fluid and electrolyte imbalances, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Kang treats.

CMS data shows 485 Medicare services from Dr. Kang across 7 procedure codes in 2024, for 153 Medicare patients. Medicare paid $27,846 for them.

CMS counts 153 Medicare patients who saw Dr. Kang in 2024. The largest group is 65 to 74, with 76 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kang's median patient age at 74, with 53% women.

In 2024, Dr. Kang wrote 329 Medicare Part D claims for 49 patients. 59% of them were for generic drugs. CMS names the drug for 258 of them, across 5 drugs with 11 or more claims each, at $3,911,077 in total drug cost. In 2023, CMS named 152 claims across 4 drugs.

Dr. Kang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kang as offering telehealth.

Dmand AI links 94 papers to Dr. Kang, published from 2003 to 2025. 2022 was the busiest year, with 8. The most frequent topics are Multiple Myeloma, Mice, Inbred C57BL and Apoptosis. Dr. Kang has published most often in J Hematol Oncol. Dr. Kang's most frequent co-authors are Luciano J. Costa, Gwynn D. Long, MD and Parker Dotson Mathews, MD.

Dmand AI links Dr. Kang to 6 clinical trials, 5 of them phase 1/2 studies. 1 is still active or recruiting. Conditions studied include Multiple Myeloma and Blood Protein Disorders. University of Alabama at Birmingham sponsors the most, 2.

CMS Open Payments shows 26 general payments to Dr. Kang from 7 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 88% of the total. Sanofi and Genzyme US Companies paid the most, $11,294.

Dmand AI lists 1 award for Dr. Kang, most recently CMS Stage 1 EHR in 2013.

Dr. Kang graduated from The Second Military Medicine Univ in 1985.

Dr. Kang is in network with 18 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.